Although with controversial results, medications such as SGLT inhibitors [31] growth hormone [32], glucagon-like peptide-1 [33], metformin [34,35], 3-Hydroxy-3 methylglutaryl coenzyme A inhibitor [36,37,38], and dipeptidyl peptidase 4 inhibitors [39,40,41] can also produce beneficial effects altering the sarcopenic’s metabolic parameters, protecting against cardiovascular diseases and outcomes while protecting muscles. The gene discussed is GH1; the disease is cardiovascular disorder.